Edgewise Therapeutics (EWTX) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Immunome (IMNM) over the past year, gaining 155.6% versus a gain of 37.8%. Over five years, EWTX leads with a +121.1% price change compared with +9.7% for IMNM. Edgewise Therapeutics is the larger company by market cap ($4.26 billion vs $2.28 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | IMNM |
|---|---|---|
| Share price | $39.23 | $19.31 |
| Market cap | $4.26B | $2.28B |
| 1-day change | -0.86% | +1.13% |
| YTD return | +58.09% | -10.10% |
| 1-year return | +155.57% | +37.83% |
| 5-year return | +121.14% | +9.65% |
| EPS (TTM) | $-1.86 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.94M |
| Revenue growth (YoY) | — | -23.23% |
| Net income (latest FY) | $-167.79M | $-212.39M |
| Operating margin | — | -3228.83% |
| Net margin | — | -3059.99% |
| 52-week high | $48.51 | $30.06 |
| 52-week low | $14.25 | $13.49 |
| Distance from 52-week high | -19.13% | -35.76% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.13% | +82.29% |
| Average volume | 1.34M | 1.20M |
| Shares outstanding | 108.60M | 118.00M |
| Employees | 127 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed IMNM by 117.7 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
EWTX vs IMNM FAQ
Which is bigger, Edgewise Therapeutics or Immunome?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.26B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, EWTX or IMNM?
EWTX returned +155.57% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.